This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh